Recommended Labs and Vaccines for a 17-Year-Old Female at Wellness Visit
A 17-year-old female at her wellness visit should receive HPV vaccine (if not completed), Tdap (if not received), meningococcal vaccines (MenACWY booster and MenB based on shared decision-making), annual influenza vaccine, and catch-up vaccines as needed; routine laboratory screening should include annual chlamydia testing and consideration for gonorrhea screening based on sexual activity and risk factors.
Immunizations
Priority Vaccines
HPV Vaccination (Highest Priority)
- Administer HPV vaccine series if not completed 1, 2
- The 3-dose series should be completed by age 26 years for catch-up vaccination
- Doses given at 0,2 months, and 6 months (minimum intervals: 4 weeks between doses 1-2, and 12 weeks between doses 2-3)
- No pre-vaccination testing for HPV DNA, HPV antibody, or Pap testing is needed 1
- Sexual activity status does not preclude vaccination—even sexually active females benefit from protection against HPV types they haven't encountered 1
Tdap Vaccine
- Verify receipt of Tdap booster (should have been given at age 11-12 years) 2
- If not received, administer now
- Tdap can be given regardless of interval since last tetanus-containing vaccine 2
Meningococcal Vaccines
- MenACWY booster dose at age 16-17 years if first dose was given at age 11-12 years 2, 3, 4
- MenB vaccine series can be offered through shared clinical decision-making for ages 16-23 years (preferred age 16-18 years) 2, 4, 5
- Two-dose series depending on formulation
- Particularly consider for college-bound students, those in congregate living settings
Annual Influenza Vaccine
Catch-Up Vaccines (If Incomplete)
Review immunization record and complete any missing vaccines:
- Hepatitis B series (3 doses) if not completed 3
- Hepatitis A series (2 doses) - now recommended for all adolescents through age 18 years 3, 4
- MMR (2 doses) if not documented 2
- Varicella (2 doses) if no history of disease and not previously vaccinated 2
Laboratory Screening
Sexually Transmitted Infection Screening
Chlamydia Screening (Essential)
- Screen annually for Chlamydia trachomatis in all sexually active females aged ≤25 years 6
- Use nucleic acid amplification test (NAAT) on urine or vaginal swab
- Rescreen 3 months after treatment if positive, regardless of partner treatment status 6
Gonorrhea Screening
- Screen annually for gonorrhea in sexually active females 6
- Consider screening every 3-6 months if high-risk factors present:
- Multiple or anonymous partners
- Sex in conjunction with illicit drug use
- New partner
- History of previous STI
- Inconsistent condom use
Risk-Based Screening
- Trichomoniasis: Not routine, but consider if high-risk factors (multiple partners, history of STIs, exchanging sex for payment) 6
- Syphilis: Not routine for heterosexual adolescents, but screen if high-risk behaviors present 6
- HIV: Offer screening based on sexual activity and risk assessment
Other Laboratory Tests
No routine laboratory tests are universally recommended for healthy 17-year-old females at wellness visits beyond STI screening in sexually active individuals. Additional testing should be based on:
- Individual risk factors
- Family history
- Specific clinical concerns
- Sexual activity status
Critical Implementation Points
Common Pitfalls to Avoid
- Missing HPV vaccination opportunities: At age 17, this is catch-up vaccination—don't delay further 1, 4
- Forgetting MenACWY booster: The 16-year booster is frequently missed 4, 5
- Not screening sexually active females for chlamydia: This is the highest-burden STI in this age group 6
- Assuming sexual activity status: Take a confidential, non-judgmental sexual history to guide STI screening 6
Documentation Needed
- Review immunization records from childhood
- Verify dates of previous vaccines to determine appropriate intervals
- Document sexual history confidentially (separate from parent discussion if minor laws permit)
- Assess for high-risk behaviors requiring enhanced STI screening
Nuances in Evidence
The guidelines consistently prioritize HPV vaccination through age 26 for catch-up, with multiple ACIP recommendations emphasizing that even sexually active adolescents benefit 1, 2. Recent surveillance data show HPV vaccination rates lag significantly behind other adolescent vaccines (58.6% up-to-date in 2020 vs. 90.1% for Tdap) 4, making this a critical intervention opportunity.
For STI screening, the evidence strongly supports routine chlamydia screening in all sexually active females ≤25 years, with gonorrhea screening based on individual and community prevalence 6. The 3-month rescreening recommendation after positive tests reflects high reinfection rates in this population.